EpiCast Report: Parkinson’s Disease - Epidemiology Forecast to 2022

Summary

Parkinson’s disease is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer’s disease, affecting 1%–2% of individuals ages =65 years worldwide.
Parkinson’s disease is associated with motor symptoms involving bradykinesia, rest tremor, rigidity, and postural disturbances, in addition to non-motor symptoms including hyposmia, rapid eye movements, sleep behavior disorder, and depression. Age, genetics, sex, and environmental exposure increase the risk of developing Parkinson’s disease. Conditions such as depression and anxiety have been identified as comorbidities in Parkinson’s disease.


In 2012, there were 2,179,414 diagnosed cases of Parkinson’s disease in the 8MM. By 2022, GlobalData epidemiologists forecast there will be 2,893,575 diagnosed cases of Parkinson’s disease in the 8MM. The US will have the highest number of cases in 2022, followed by Brazil and Japan.


The 8MM will be important markets for Parkinson’s disease during the next 10 years because these countries have a growing older population. Japan’s current and growing elderly population is the strongest contributor and key driver for increases in Parkinson’s disease prevalent cases in Japan. With greater advances in accurately detecting and diagnosing Parkinson’s disease in addition to creating a globally and nationally recognized Parkinson’s disease registry, we can help further improve our epidemiological understanding of this disorder.

Scope

- The Parkinson’s disease EpiCast Report provides an overview of the risk factors and comorbidities for Parkinson’s disease in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Brazil). It includes a 10-year epidemiological forecast of diagnosed prevalent cases of Parkinson’s disease segmented by sex and age (ages 65–85+ years).

- The Parkinson’s disease epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global Parkinson’s disease market.

- Quantify patient populations in the global Parkinson’s disease market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Parkinson’s disease therapeutics in each of the markets covered.

Table Of Contents

Table of Contents

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Upcoming Reports 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 7
3.2.1 The risk of developing Parkinson’s disease progressively increases with age 8
3.2.2 The risk for Parkinson’s disease is increased with Parkinson’s disease-causing mutations 9
3.2.3 Men are 1.5 times more likely to develop Parkinson’s disease than women, though the difference may be the result of varying exposures to environmental factors 9
3.2.4 Chemicals, along with exposure to other environmental factors, increase the risk of developing Parkinson’s disease 10
3.2.5 38% of Parkinson’s disease cases experienced depression and/or anxiety compared with only 8% of controls 11
3.3 Global Trends 11
3.3.1 US 11
3.3.2 5EU 12
3.3.3 Japan 13
3.3.4 Brazil 13
3.4 Forecast Methodology 14
3.4.1 Sources Used 15
3.4.2 Sources Not Used 18
3.4.3 Forecast Assumptions and Methods 18
3.5 Epidemiological Forecast of Parkinson’s Disease (2012-2022) 20
3.5.1 Prevalent Cases of Parkinson’s Disease 20
3.5.2 Age-Specific Prevalent Cases of Parkinson’s Disease 21
3.5.3 Sex-Specific Prevalent Cases of Parkinson’s Disease 23
3.5.4 Age-Standardized Prevalence of Parkinson’s Disease 24
3.6 Discussion 25
3.6.1 Epidemiological Forecast Insight 25
3.6.2 Limitations of the Analysis 26
3.6.3 Strengths of the Analysis 27
4 Appendix 28
4.1 Bibliography 28
4.2 About the Authors 31
4.2.1 Epidemiologists 31
4.2.2 Reviewers 31
4.2.3 Global Director of Epidemiology and Health Policy 33
4.2.4 Global Head of Healthcare 33
4.3 About GlobalData 34
4.4 About EpiCast 34
4.5 Disclaimer 35



List of Tables

Table 1: Risk Factors and Comorbidities for Parkinson’s Disease 8
Table 2: Sources of Diagnosed Prevalence Data Used in the Epidemiology Forecast 15
Table 3: 8MM, Diagnosed Prevalent Cases of Parkinson’s Disease, Ages ?65 Years, Both Sexes, N, Select Years, 2012-2022 20
Table 4: 8MM, Diagnosed Prevalent Cases of Parkinson’s Disease, by Age, N (Row %), 2012 22
Table 5: 8MM, Diagnosed Prevalent Cases of Parkinson’s Disease, by Sex, N (Row %), 2012 23



List of Figures

Figure 1: 8MM, Age-Adjusted Mortality Rate of Parkinson’s Disease, Both Sexes, N, 2011 14
Figure 2: 8MM, Diagnosed Prevalent Cases of Parkinson’s Disease, Ages ?65 Years, Both Sexes, N, Select Years, 2012-2022 21
Figure 3: 8MM, Diagnosed Prevalent Cases of Parkinson’s Disease, by Age, N, 2012 22
Figure 4: 8MM, Diagnosed Prevalent Cases of Parkinson’s Disease, by Sex, N, 2012 24
Figure 5: 8MM, Age-Standardized Prevalence (%) of Parkinson’s Disease, 2012 25

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 Summary Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, ...

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Analytical Tool - Hematological Cancers

Analytical Tool - Hematological Cancers

  • $ 8 925
  • Industry report
  • March 2014
  • by Bioseeker

"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.